Wockhardt Ltd has informed the BSE that the company has received approval from the Drug Controller General of India to conduct Phase I clinical trials on its new chemical entity 'WCK 1152' |
Top Section
Explore Business Standard
Don’t miss the latest developments in business and finance.
Wockhardt Ltd has informed the BSE that the company has received approval from the Drug Controller General of India to conduct Phase I clinical trials on its new chemical entity 'WCK 1152' |
First Published: May 05 2004 | 12:00 AM IST